Towards a Viral Etiology of Periodontal Disease in Relation to Radiotherapy Treatment of Head and Neck Cancers

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02180932

Enrollment

Registered

2014-07-03

Start date

2014-10-20

Completion date

2015-12-03

Last updated

2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Disease

Brief summary

The treatment of otolaryngology (OLR) cancer is based on surgery, radiation, sometimes used in combination with chemotherapy. Patients treated with radiotherapy have multiple oral diseases: mucositis, hyposalivation, tissue fibrosis, exacerbation of periodontitis. Over 70% of patients with head and neck cancers treated with radiotherapy have a lower level of dental clinical attachment and 92% have loose teeth or missing. The management of these oral complications is a priority in OLR oncology. The aim is to improve the oral health of patients to achieve a comfortable life acceptable and necessary for healing. This project proposes to deepen the investigation with two main objectives: 1. To study in vivo the effect of radiation treatment on the evolution of the viral flora of the periodontium in a cohort of patients and matched controls. 2. To study in vitro the effects of irradiation on the replication EBV (herpesvirus) in producing websites lymphoepithelial tonsillar, and atypical dendritic cells associated with EBV that existence were recently discovered.

Interventions

BIOLOGICALperiodontal pocket samples

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients ≥ 18 years * Patients treated with curative radiotherapy on tumor site or surgery for cancer of the oral cavity and / or oropharynx * Patients naive treatments for head and neck cancers * Patients affiliated or beneficiary of a social security scheme * Patients who gave informed consent in writing

Exclusion criteria

* Patients treated with neoadjuvant chemotherapy, adjuvant or concomitant * Patients taking immunosuppressants after organ transplantation * Taking anticoagulants incompatible with dental samples (possible bleeding) * Patients edentulous and / or whose dental condition is incompatible with the dental samples

Design outcomes

Primary

Measure	Time frame
Measure of level of EBV nucleic acids	day 1

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026